Monoclonal antibodies (mAbs) have transformed modern medicine [1]. However, their impact is limited as they are not accessible to all. In 2020 IAVI and Wellcome published a joint report “Expanding access to monoclonal antibody — based products: a global call to action” [2] which highlighted the gaps and opportunities to expand access to mAbs in low- and middle-income countries (LMICs). The report revealed that few, if any, mAbs were available in LMICs,
Links:
[1] http://admin.indiaenvironmentportal.org.in/reports-documents/access-monoclonal-antibodies-africa-call-action
[2] http://admin.indiaenvironmentportal.org.in/category/publisher/iavi-and-impact-global-health
[3] http://admin.indiaenvironmentportal.org.in/category/thesaurus/africa
[4] http://admin.indiaenvironmentportal.org.in/category/thesaurus/health-care
[5] http://admin.indiaenvironmentportal.org.in/category/thesaurus/antimicrobial-resistance